HF
ATNM icon

HRT Financial’s Actinium Pharmaceuticals ATNM Stock Holding History

HRT Financial’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,010
Closed -$17K – 3757
2025
Q4 		$17K Buy
+13,010
New +$19K ﹤0.01% 2998
2025
Q3 		– Sell
-27,476
Closed -$38K – 2841
2025
Q2 		$38K Buy
+27,476
New +$41.1K ﹤0.01% 2339
2023
Q2 		– Sell
-62,533
Closed -$590K – 2447
2023
Q1 		$590K Buy
+62,533
New +$660K 0.01% 1247
2019
Q4 		– Sell
-1,074
Closed -$7K – 1142
2019
Q3 		$7K Buy
+1,074
New +$7.48K ﹤0.01% 1358

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's ATNM Position: Q1 2026 in Review

HRT Financial sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 13,010 shares — an estimated $17K sold.

HRT Financial first reported a position in ATNM in Q3 2019 and held it in 4 quarters. The position peaked at $590K in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • HRT Financial reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 13,010 Actinium Pharmaceuticals shares in Q1 2026, an estimated $17K.
  • HRT Financial first reported a position in Actinium Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • HRT Financial's Actinium Pharmaceuticals position peaked at $590K in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.